Envoya develops a drug-delivery platform for gene therapy that combines engineered biopolymer-nanoparticles with artificial intelligence. The platform is designed to address limitations of viral vectors and lipid nanoparticles, including safety, payload capacity, and tissue targeting. Early preclinical experiments have shown promising results in multiple oncology indications and genetic diseases. Envoya emerged from stealth with a soft launch and is backed by over $2 million in pre-seed funding. The company is led by founder and CEO Dr. Shira Orr (postdoctoral work at Harvard Medical School) and board chairman Eran Orr, with CPO Ori Shaashua, VP Alysa Langburt, and VP Trinayan Kashyap rounding out the leadership team. Envoya says it is actively pursuing partnerships to expand its platform's reach and advance preclinical development toward therapeutic applications.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2023